Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

7.1%

3 terminated/withdrawn out of 42 trials

Success Rate

92.9%

+6.4% vs industry average

Late-Stage Pipeline

43%

18 trials in Phase 3/4

Results Transparency

85%

33 of 39 completed trials have results

Key Signals

33 with results

Enrollment Performance

Analytics

Phase 3
18(42.9%)
Phase 2
14(33.3%)
Phase 1
10(23.8%)
42Total
Phase 3(18)
Phase 2(14)
Phase 1(10)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (42)

Showing 20 of 42 trials
NCT02536508Phase 3Completed

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Role: lead

NCT02465567Phase 3Completed

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

Role: lead

NCT03250182Phase 1Completed

A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose

Role: lead

NCT03075267Phase 1Completed

Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects

Role: lead

NCT02497001Phase 3Completed

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)

Role: lead

NCT02109406Phase 2Completed

Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD

Role: lead

NCT03358147Phase 2Completed

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

Role: lead

NCT03311373Phase 1Completed

A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010

Role: lead

NCT03262012Phase 3Completed

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

Role: lead

NCT02727660Phase 3Completed

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

Role: lead

NCT02766608Phase 3Completed

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

Role: lead

NCT02685293Phase 3Terminated

Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD

Role: lead

NCT02937584Phase 3Completed

A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

Role: lead

NCT02643082Phase 3Completed

A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

Role: lead

NCT02343458Phase 3Completed

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Role: lead

NCT03081247Phase 3Withdrawn

To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Role: lead

NCT02347085Phase 3Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

Role: lead

NCT01350128Phase 2Completed

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Role: lead

NCT02196077Phase 2Completed

Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Role: lead

NCT02189304Phase 1Completed

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

Role: lead